Abstract
Background
Intercellular adhesion molecule-1 (ICAM-1) is implicated in carcinogenesis. In this study we examined the expression of ICAM-1 in papillary thyroid cancer (PTC). We hypothesized that ICAM-1 correlates with indicators of tumor aggressiveness in PTC.
Methods
Thirty-five primary and metastatic PTCs, five follicular adenomas, five Hashimoto thyroiditis, five nodular hyperplasia, and eight normal thyroid tissue samples were analyzed for ICAM-1 gene expression using quantitative reverse-transcription polymerase chain reaction (RT-PCR). ICAM-1 gene expression was analyzed at protein level by immunohistochemistry (IHC) using a semiquantitative score. Gene expression and intensity levels were correlated with markers of tumor aggressiveness including BRAF V600E mutation, tumor size, extrathyroidal extension (ETE), angiolymphatic invasion, and lymph node metastasis.
Results
ICAM-1 gene expression was higher in PTC (p = 0.01) and lymph node metastases (p = 0.03) when compared with benign tumors and Hashimoto’s. Furthermore, PTCs exhibiting BRAF V600E mutation (p = 0.01), ETE (p < 0.01), and lymph node metastasis (p = 0.02) were associated with higher ICAM-1 levels. Gene expression correlated with protein levels on IHC. Additionally, poorly differentiated thyroid carcinoma had a higher ICAM-1 intensity score compared with well-differentiated carcinoma (p = 0.03).
Conclusions
ICAM-1 expression is upregulated in papillary thyroid carcinoma. Furthermore, ICAM-1 upregulation correlated with aggressive tumor features such as BRAF V600E mutation, ETE, and lymph node metastasis, suggesting that ICAM-1 plays a role in thyroid cancer progression.
Similar content being viewed by others
References
Rivera M, Ghossein RA, Schoder H, et al. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer. 2008;113:48–56.
Yang L, Froio RM, Sciuto TE, et al. ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow. Blood. 2005;106:584–92.
Hayes SH, Seigel GM. Immunoreactivity of ICAM-1 in human tumors, metastases and normal tissues. Int J Clin Exp Pathol. 2009;2:553–60.
Nakashima M, Eguchi K, Ishikawa N, et al. Expression of adhesion molecule ICAM-1 (CD54) in thyroid papillary adenocarcinoma. J Endocrinol Invest. 1994;17:843–8.
Lin YC, Shun CT, Wu MS, Chen CC. A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin Cancer Res. 2006;12:7165–73.
Skelding KA, Barry RD, Shafren DR. Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21. Breast Cancer Res Treat. 2009;113:21–30.
Basoglu M, Atamanalp SS, Yildirgan MI, et al. Correlation between the serum values of soluble intercellular adhesion molecule-1 and total sialic acid levels in patients with breast cancer. Eur Surg Res. 2007;39:136–40.
Pasieka Z, Kuzdak K, Czyz W, et al. Soluble intracellular adhesion molecules (sICAM-1, sVCAM-1) in peripheral blood of patients with thyroid cancer. Neoplasma. 2004;51:34–7.
Melis M, Spatafora M, Melodia A, et al. ICAM-1 expression by lung cancer cell lines: effects of upregulation by cytokines on the interaction with LAK cells. Eur Respir J. 1996;9:1831–8.
Park S, Kang S, Veach AJ, et al. Self-assembled nanoplatform for targeted delivery of chemotherapy agents via affinity-regulated molecular interactions. Biomaterials. 2010;31:7766–75.
Arora N, Scognamiglio T, Lubitz CC, et al. Identification of borderline thyroid tumors by gene expression array analysis. Cancer. 2009;115:5421–31.
Pfeiffer P, Nexo E, Bentzen SM, et al. Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis. Br J Cancer. 1998;78:96–9.
Tanda F, Cossu A, Bosincu L, et al. Intercellular adhesion molecule-1 (ICAM-1) immunoreactivity in well-differentiated thyroid papillary carcinomas. Mod Pathol. 1996;9:53–6.
Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid Off J Am Thyroid Assoc. 2006;16:109–42.
Andersen PE, Kinsella J, Loree TR, et al. Differentiated carcinoma of the thyroid with extrathyroidal extension. Am J Surg. 1995;170:467–70.
Mazzaferri EL. Papillary thyroid carcinoma: factors influencing prognosis and current therapy. Semin Oncol. 1987;14:315–32.
Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947–53.
Arora N, Turbendian HK, Scognamiglio T, et al. Extrathyroidal extension is not all equal: implications of macroscopic versus microscopic extent in papillary thyroid carcinoma. Surgery. 2008;144:942–7 (discussion 947–8).
Pfister DG, Fagin JA. Refractory thyroid cancer: a paradigm shift in treatment is not far off. J Clin Oncol. 2008;26:4701–4.
Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009;69:4885–93.
Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28:742–62.
Riesco-Eizaguirre G, Rodriguez I, De la Vieja A, et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 2009;69:8317–25.
Derhaag JG, Duijvestijn AM, Van Breda Vriesman PJ. Heart EC respond heterogeneous on cytokine stimulation in ICAM-1 and VCAM-1, but not in MHC expression. A study with 3 rat heart endothelial cell (RHEC) lines. Endothel J Endothel Cell Res. 1997;5:307–19.
Murakami T, Mataki C, Nagao C, et al. The gene expression profile of human umbilical vein endothelial cells stimulated by tumor necrosis factor alpha using DNA microarray analysis. J Atheroscler Thromb. 2000;7:39–44.
Hu G, Gong AY, Liu J, et al. miR-221 suppresses ICAM-1 translation and regulates interferon-gamma-induced ICAM-1 expression in human cholangiocytes. Am J Physiol Gastrointest Liver Physiol. 2010;298:G542–50.
Ueda R, Kohanbash G, Sasaki K, et al. Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci USA. 2009;106:10746–51.
Lin FS, Lin CC, Chien CS, et al. Involvement of p42/p44 MAPK, JNK, and NF-kappaB in IL-1beta-induced ICAM-1 expression in human pulmonary epithelial cells. J Cell Physiol. 2005;202:464–73.
Yan W, Jiang Y, Huang Q. [The role of p38 MAPK in LPS induced ICAM-1 expression on endothelial cell]. Zhonghua shao shang za zhi (Chin J Burns). 2001;17:32–5.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Buitrago, D., Keutgen, X.M., Crowley, M. et al. Intercellular Adhesion Molecule-1 (ICAM-1) is Upregulated in Aggressive Papillary Thyroid Carcinoma. Ann Surg Oncol 19, 973–980 (2012). https://doi.org/10.1245/s10434-011-2029-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-011-2029-0